Marksans Pharma’s arm gets UK MHRA approval for Fluoxetine Oral Solution
23rd Jan 2023

UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Market Authorisation to Marksans Pharma’s wholly owned subsidiary Relonchem for Fluoxetine 20mg/5ml Oral Solution.

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders. The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.